A. Laino

发表

High-Parameter Single-Cell Analysis.

P. Chattopadhyay, A. Winters, Woodrow E. Lomas, 2019, Annual review of analytical chemistry.

HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics

David M. Woods, I. Dolgalev, A. Laino, 2019, Journal of Immunotherapy for Cancer.

Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells

David M. Woods, A. Laino, D. Woods, 2020, Clinical Cancer Research.

Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition

David M. Woods, A. Laino, D. Woods, 2020, Journal for immunotherapy of cancer.

Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma

David M. Woods, A. Laino, D. Woods, 2022, Melanoma research.

Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition.

J. Wolchok, J. Larkin, F. Hodi, 2019, Journal of Clinical Oncology.

Targeting Histone Deacetylases in Melanoma and T-cells to Improve Cancer Immunotherapy

A. Laino, Andressa Laino, 2016 .

Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma

David M. Woods, A. Laino, D. Woods, 2018, Clinical Cancer Research.

Preclinical and clinical studies of a class I/IV HDAC inhibitor, mocetinostat, in melanoma.

A. Laino, D. Woods, A. Pavlick, 2020 .

Nivolumab and ipilimumab are associated with distinct immune landscape changes and response-associated immunophenotypes.

David M. Woods, Santi S. Adavani, P. Chattopadhyay, 2020, JCI insight.

A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral (iTu) injection alone and in combination with durvalumab.

R. Sullivan, A. Jimeno, P. LoRusso, 2020 .

C reactive protein impairs adaptive immunity in immune cells of patients with melanoma

David M. Woods, A. Laino, D. Woods, 2020, Journal for ImmunoTherapy of Cancer.